Premium
Denosumab‐related osteonecrosis of the jaw: A retrospective study
Author(s) -
EgloffJuras Claire,
Gallois Aurélie,
Salleron Julia,
Massard Vincent,
Dolivet Gilles,
Guillet Julie,
Phulpin Bérengère
Publication year - 2018
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12646
Subject(s) - denosumab , medicine , osteonecrosis of the jaw , retrospective cohort study , incidence (geometry) , dentistry , medical record , surgery , bisphosphonate , osteoporosis , physics , optics
Background Osteonecrosis of the jaw is a very delicate side effect of Denosumab. The aim of this retrospective study was to assess the occurrence rate of Denosumab‐related osteonecrosis of the jaw ( DRONJ ) at the Cancer Institute of Lorraine ( ICL ) and to highlight necrosis risk factors. Methods To that purpose, we analyzed the medical records of 249 consecutive patients treated with Denosumab at the ICL during the past 5 years. Patients who received orofacial radiotherapy or a previous treatment with a bisphosphonate were excluded. The P ‐value was set at .005. Results A total of 141 patients treated at the ICL between January 2010 and December 2015 were included. All patients were treated with XGEVA ® . Of the 141 patients included in the study, 10 developed DRONJ . The incidence of DRONJ increases with the duration of follow‐up as follows: 3% at 1 year, 7% at 2 years, and 8% from 30 months on. No risk factor for necrosis could be identified except the realization of prior dental extraction ( P = .025). Conclusion Our results raise important questions about the dental management of these patients, in particular, concerning the healing period between dental extractions and the initiation of Denosumab.